Machine learning for comprehensive forecasting of Alzheimer's Disease progression

Most approaches to machine learning from electronic health data can only predict a single endpoint.The ability to simultaneously simulate dozens of patient characteristics is a crucial step towardspersonalized medicine for Alzheimer's Disease. Here, we use an unsupervised machine learning model called a Conditional Restricted Boltzmann Machine (CRBM) to simulate detailed patient trajectories.We use data comprising 18-month trajectories of 44 clinical variables from 1909 patients with MildCognitive Impairment or Alzheimer's Disease to train a model for personalized forecasting of disease progression. We simulate synthetic patient data including the evolution of each sub-component of cognitive exams, laboratory tests, and their associations with baseline clinical characteristics. Synthetic patient data generated by the CRBM accurately reflect the means, standard deviations, and correlations of each variable over time to the extent that synthetic data cannot be distinguished from actual data by a logistic regression. Moreover, our unsupervised model predicts changes in total ADAS-Cog scores with the same accuracy as specifically trained supervised models, additionally capturing the correlation structure in the components of ADAS-Cog, and identifies sub-components associated with word recall as predictive of progression.

Enter your email address to download paper.

Click the link to begin download.
Oops! Something went wrong while submitting the form.

Enter your email address to watch the webinar.

Click the link to watch webinar.
Oops! Something went wrong while submitting the form.
Webinars

Why can’t we agree on how to define digital twins in healthcare?

White Papers

Summary of the EMA September 2022 Qualification Opinion for PROCOVA™

Press

Charles Fisher, Unlearn.AI: “now is the time to adopt AI-based solutions”

The potential for AI implementation in healthcare can barely be measured, as it can already do what humans do, just countless times better and more efficiently.
The European Medicines Agency has qualified Unlearn’s AI-powered method for running smaller, faster clinical trials.
Digital twins seem to be everywhere in healthcare now, but no one agrees on a single definition for them.